Momentum provides a range of high throughput mass spectrometry screening technologies to identify hits for small molecule inhibitors, degraders, covalent binders, PPI inhibitors, and those targeting RNA, followed by cell based chemoprotoemic assays to further probe signals of future clinical utility. This signaling information allows biopharma researchers to make better decisions when selecting and prioritizing compounds during discovery and preclinical development.
BILLERICA, Mass. and MUNICH, Germany Mar. 5, 2025 Momentum Biotechnologies (“Momentum”), a contract research organization (“CRO”) specializing in mass spectrometry-based drug discovery, announced today that it has successfully completed the acquisition of OmicScouts GmbH (“OmicScouts”), a Munich-based CRO and established […]
BILLERICA, MA, November 29, 2023. Momentum Biotechnologies, a leading provider of mass spectrometry-based analytical drug discovery services, has announced the launch of new services focused on proteomics. Offerings will include targeted and global proteomics, chemoproteomics and comparative proteomics using TMT-labelling […]
BILLERICA, MA, USA and MILAN, ITALY, November 15, 2023. Axxam S.p.A. and Momentum Biotechnologies have announced a partnership to provide unique drug discovery solutions for biotechnology and pharmaceutical clients. Through the partnership Axxam’s highly curated chemical diversity library, comprised of […]
BILLERICA, Mass., Sept. 13, 2023 /PRNewswire/ — Momentum Biotechnologies (“Momentum” or the “Company”), a leading contract research organization (“CRO”) specializing in mass spectrometry-based native detection technologies, is pleased to announce the appointment of Dr. Kevin Bateman to its Scientific Advisory Board. Dr. Bateman has 25+ years […]
BILLERICA, MA (Aug. 10, 2023) – Momentum Biotechnologies (“Momentum” or the “Company”), a leading contract research organization (“CRO”) specializing in mass spectrometry-based native detection technologies, is pleased to announce the appointment of Harvard Medical School Professor Dr. Ying Lu to its Scientific […]
Billerica, MA – Momentum Biotechnologies, formerly known as PureHoney Technologies, is a leading CRO focused on providing mass spectrometry-based native detection technologies for lead discovery and the quantification of difficult targets to biopharmaceutical clients globally. The new name better reflects […]
© Care Equity Capital Management L.P. New York, New York
